PE20030806A1 - Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo - Google Patents

Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo

Info

Publication number
PE20030806A1
PE20030806A1 PE2003000098A PE2003000098A PE20030806A1 PE 20030806 A1 PE20030806 A1 PE 20030806A1 PE 2003000098 A PE2003000098 A PE 2003000098A PE 2003000098 A PE2003000098 A PE 2003000098A PE 20030806 A1 PE20030806 A1 PE 20030806A1
Authority
PE
Peru
Prior art keywords
controlled release
transfer protein
cholesteryl ester
dosing
protein inhibitor
Prior art date
Application number
PE2003000098A
Other languages
English (en)
Inventor
Leah Elizabeth Appel
Steven Charles Sutton
William John Curatolo
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20030806A1 publication Critical patent/PE20030806A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

QUE COMPRENDE: A)UNA FORMA DE SOLUBILIDAD POTENCIADA DE UN INHIBIDOR DE PROTEINA DE TRANSFERENCIA DE ESTER DE COLESTERILO (CETPI), QUE ES ESTER ETILICO DEL ACIDO [1R,4S]-4-[(3,5-BISTRIFLUOROMETILBENCIL)METOXICARBONILAMINO]-2-ETIL-6-TRIFLUOROMETIL-3,4-DIHIDRO-2H-QUINOLIN-1-CARBOXILICO; Y, B)UN MEDIO DE LIBERACION CONTROLADA PARA LIBERAR CETPI. DONDE, DESPUES DE LA ADMINISTRACION A UN ENTORNO DE USO IN VIVO, LA CITADA FORMA DE LIBERACION CONTROLADA PROPORCIONA AL MENOS UNO DE LO SIGUIENTE: 1)AL MENOS UN 50% DE INHIBICION DE LA PROTEINA PLASMATICA DE TRANSFERENCIA DE ESTER DE COLESTERILO DURANTE AL MENOS 12 HORAS; 2)UNA CONCENTRACION MAXIMA DE FARMACO EN LA SANGRE MENOR O IGUAL A 80% DE LA CONCENTRACION MAXIMA DE FARMACO EN LA SANGRE PROPORCIONADA POR UNA FORMA DE DOSIFICACION DE LIBERACION INMEDIATA CONSTITUIDA POR LA MISMA CANTIDAD DE LA FORMA DE SOLUBILIDAD POTENCIADA DEL CETPI; iii) UN NIVEL MEDIO DE COLESTEROL HDL DESPUES DE LA DOSIFICACION DURANTE 8 SEMANAS QUE ES AL MENOS APROXIMADAMENTE 1,2 VECES EL OBTENIDO ANTES DE LA DOSIFICACION; Y, iv)UN NIVEL MEDIO DE COLESTEROL LDL DESPUES DE LA DOSIFICACION DURANTE 8 SEMANAS QUE ES MENOR O IGUAL AL 90% DEL OBTENIDO ANTES DE LA DOSIFICACION
PE2003000098A 2002-02-01 2003-01-29 Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo PE20030806A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35371902P 2002-02-01 2002-02-01

Publications (1)

Publication Number Publication Date
PE20030806A1 true PE20030806A1 (es) 2003-09-19

Family

ID=27663244

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000098A PE20030806A1 (es) 2002-02-01 2003-01-29 Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo

Country Status (24)

Country Link
US (1) US20030198674A1 (es)
EP (1) EP1474144B1 (es)
JP (1) JP2005522424A (es)
KR (1) KR20040083493A (es)
CN (1) CN1625397A (es)
AR (1) AR038385A1 (es)
AT (1) ATE403432T1 (es)
BR (1) BR0307332A (es)
CA (1) CA2473991C (es)
DE (1) DE60322665D1 (es)
ES (1) ES2309294T3 (es)
GT (1) GT200300023A (es)
HN (1) HN2003000054A (es)
IL (1) IL162870A0 (es)
MX (1) MXPA04005647A (es)
NO (1) NO20043506L (es)
PA (1) PA8565101A1 (es)
PE (1) PE20030806A1 (es)
PL (1) PL371416A1 (es)
RU (1) RU2004123637A (es)
TW (1) TW200303204A (es)
UY (1) UY27643A1 (es)
WO (1) WO2003063868A1 (es)
ZA (1) ZA200404718B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0307333A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Métodos para a preparação de dispersões homogéneas de fármacos sólidos amorfos atomizados utilizando um sistema de secagem por pulverização
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US20040122048A1 (en) * 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
AU2003283769A1 (en) * 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
WO2004085996A2 (en) * 2003-03-20 2004-10-07 Albert Einstein College Of Medicine Of Yeshiva University Biomarkers for longevity and disease and uses thereof
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
PL1670768T3 (pl) 2003-10-08 2010-01-29 Lilly Co Eli Związki i sposoby leczenia dyslipidemii
ATE500819T1 (de) * 2003-12-31 2011-03-15 Bend Res Inc Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren
ES2308477T3 (es) 2004-03-26 2008-12-01 Eli Lilly And Company Compuestos para el tratamiento de la dislipidemia.
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
US8604055B2 (en) * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CA2605214C (en) 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
US9265731B2 (en) * 2005-01-28 2016-02-23 Bend Research, Inc. Drying of drug-containing particles
US20080145427A1 (en) * 2005-02-03 2008-06-19 Alfred Berchielli Dosage Forms Providing Controlled and Immediate Release of Cholesteryl Ester Transfer Protein Inhibitors and Immediate Release of Hmg-Coa Reductase Inhibitors
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
KR101418267B1 (ko) * 2006-02-09 2014-07-11 머크 샤프 앤드 돔 코포레이션 Cetp 억제제의 중합체 제형
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2008012617A1 (en) * 2006-07-21 2008-01-31 Pfizer Products Inc. Drying of drug-containing particles
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
WO2008065506A2 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles comprising enteric polymers and casein
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
US8105625B2 (en) * 2007-04-05 2012-01-31 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
US8900629B2 (en) 2007-04-05 2014-12-02 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
NZ580777A (en) 2007-04-13 2011-05-27 Kowa Co Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
ES2692437T3 (es) * 2007-08-13 2018-12-03 Abuse Deterrent Pharmaceutical Llc Fármacos resistentes al abuso, método de uso y método de preparación
MX2011013080A (es) * 2009-06-16 2012-01-20 Pfizer Formas de dosis de apixaban.
EP2744803A2 (en) 2011-08-18 2014-06-25 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
JP6140168B2 (ja) 2011-09-27 2017-05-31 ドクター レディズ ラボラトリーズ リミテッド アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質(cetp)インヒビターとしての5−ベンジルアミノメチル−6−アミノピラゾロ[3,4−b]ピリジン誘導体
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
KR101610465B1 (ko) 2014-04-11 2016-04-07 국립암센터 다목적용 의료 영상 표지자 및 이의 제조방법
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CN104474553A (zh) * 2014-11-26 2015-04-01 嘉应学院医学院 一种基于β-谷甾醇的药物缓释剂及其制备方法
CN107098946B (zh) * 2016-02-23 2021-01-29 中国药科大学 Cetp抑制剂的合成与用途
EP3990845B1 (en) 2019-06-26 2024-04-17 Carrier Corporation Transportation refrigeration unit with adaptive defrost
CN116472044A (zh) * 2020-09-18 2023-07-21 百时美施贵宝公司 包含可溶胀核芯的Tyk2抑制剂的剂型

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US28895A (en) * 1860-06-26 Machine for wetting paper
US91643A (en) * 1869-06-22 Improvement in gang-plows
US18446A (en) * 1857-10-20 Improvement in steam-plows
US54038A (en) * 1866-04-17 Improvement in priming metallic cartridges
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4247498A (en) 1976-08-30 1981-01-27 Akzona Incorporated Methods for making microporous products
US4564488A (en) 1978-07-31 1986-01-14 Akzo Nv Methods for the preparation of porous fibers and membranes
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4490431A (en) 1982-11-03 1984-12-25 Akzona Incorporated 0.1 Micron rated polypropylene membrane and method for its preparation
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5225192A (en) 1988-10-17 1993-07-06 Vectorpharma International S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE4316537A1 (de) 1993-05-18 1994-11-24 Basf Ag Zubereitungen in Form fester Lösungen
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US6054136A (en) 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
JPH09501186A (ja) * 1994-11-12 1997-02-04 株式会社エルジ化学 コレステリルエステル運搬蛋白質阻害ペプチドおよびこれを含む動脈硬化症のための予防および治療剤
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
US5686133A (en) 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
US5993858A (en) 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
DE69935992T4 (de) 1998-09-25 2008-05-29 Monsanto Co., Chicago Polycyclische aryl und heteroaryl substituierte tertiäre heteroalkylamine, für die hemmung der aktivität des cholesteryl-ester-transfer-proteins
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
ATE404178T1 (de) * 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1712222A3 (en) 1999-12-23 2012-06-20 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
DE60038698T2 (de) * 1999-12-23 2009-05-07 Pfizer Products Inc., Groton Hydrogel-gesteuerte dosierungsform
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
JP4547148B2 (ja) * 2001-06-22 2010-09-22 ベンド・リサーチ・インコーポレーテッド 非晶質薬剤の吸着物の医薬組成物
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo

Also Published As

Publication number Publication date
UY27643A1 (es) 2003-08-29
EP1474144B1 (en) 2008-08-06
JP2005522424A (ja) 2005-07-28
NO20043506L (no) 2004-10-19
ES2309294T3 (es) 2008-12-16
BR0307332A (pt) 2004-12-07
HN2003000054A (es) 2003-11-24
MXPA04005647A (es) 2005-03-23
KR20040083493A (ko) 2004-10-02
RU2004123637A (ru) 2005-04-20
ATE403432T1 (de) 2008-08-15
IL162870A0 (en) 2005-11-20
US20030198674A1 (en) 2003-10-23
CA2473991C (en) 2009-09-15
WO2003063868A1 (en) 2003-08-07
GT200300023A (es) 2003-09-17
ZA200404718B (en) 2006-11-29
PL371416A1 (en) 2005-06-13
EP1474144A1 (en) 2004-11-10
CN1625397A (zh) 2005-06-08
PA8565101A1 (es) 2003-11-12
CA2473991A1 (en) 2003-08-07
AR038385A1 (es) 2005-01-12
DE60322665D1 (de) 2008-09-18
TW200303204A (en) 2003-09-01

Similar Documents

Publication Publication Date Title
PE20030806A1 (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo
RU2401658C2 (ru) Гетероциклические ингибиторы аспартилпротеазы
CL2010000434A1 (es) Uso de una composicion farmaceutica que comprende vitamina b12 y acido n-(8-(2-hidroxibenzoil)animo) caprilico o sus sales para preparar un medicamento util en el tratamiento de la deficiencia de vitamina b12; composicion farmaceutica.
EA200870154A1 (ru) Лекарственное средство для местного применения
DK1885333T3 (da) Farmaceutisk formulering af apomorphin til bukkal indgivelse
EA201190127A1 (ru) Фармацевтические составы нитазоксанида с контролируемым высвобождением
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
EA200400154A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
UY29905A1 (es) Formulación farmacéutica de absorción oral y su método de administración
DK0828724T3 (da) 5-oxygenerede diaryl-2-(5H)-furanoner som COX-2-inhibitorer
UY27740A1 (es) Nuevos compuestos
CA2515293A1 (en) Eicosapentaenoic acid for use in improving prognosis in the treatment of subarachnoid hemorrhage
NO20060329L (no) Paratyroid hormon (PTH) inneholdende farmasoytiske sammensetninger for oral anvendelse
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
RU2013148120A (ru) Интраназальные фармацевтические композиции на основе бензодиазепина
PE20141032A1 (es) Inhibidores del virus de la hepatitis c
AR051797A1 (es) Derivados de hidantoina inhibidores de metaloproteinasas
AR031117A1 (es) Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica
EA200301019A1 (ru) Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор cox-2), растворитель, жирную кислоту и органический амин
TN2009000504A1 (en) Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
ECSP067074A (es) Derivados de 4-fenil-pirimidina-2-carbonitrilo
EA200870153A1 (ru) Композиция и способ ее использования
AR035553A1 (es) Formas cristalinas de melagatran, proceso para su produccion, formulacion farmaceutica, y uso de este compuesto en la elaboracion de medicamentos.

Legal Events

Date Code Title Description
FD Application declared void or lapsed